Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Phio Pharmaceuticals Corp. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −5 vs. Q2 2024
- Shares held
- 28.5K
- −139.6K (−83.0%) vs. Q2 2024
- Total value
- $98.3K
- −$18.6K (−15.9%) vs. Q2 2024
- New holders
- 2
- 0 more added
- Sold out
- 7
- 4 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $662.6K |
| Q1 2026 | 24 | $815.0K |
| Q4 2025 | 17 | $382.3K |
| Q3 2025 | 11 | $467.4K |
| Q2 2025 | 11 | $387.4K |
| Q1 2025 | 11 | $130.8K |
| Q4 2024 | 11 | $277.4K |
| Q3 2024 | 6 | $98.3K |
| Q2 2024 | 12 | $117.0K |
| Q1 2024 | 10 | $106.1K |
| Q4 2023 | 14 | $388.8K |
| Q3 2023 | 14 | $445.4K |
| Q2 2023 | 13 | $798.3K |
| Q1 2023 | 8 | $219.7K |
| Q4 2022 | 12 | $213.2K |
| Q3 2022 | 15 | $415.0K |
| Q2 2022 | 13 | $551.0K |
| Q1 2022 | 15 | $626.0K |
| Q4 2021 | 18 | $991.0K |
| Q3 2021 | 16 | $1.82M |
| Q2 2021 | 17 | $1.58M |
| Q1 2021 | 16 | $1.34M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Phio Pharmaceuticals Corp.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 25,131 | $86.7K | 1.20% | +25,131 | New |
| UBS Group AG | 1,685 | $5.81K | 0.00% | −762−31.1% | Reduced |
| Tower Research Capital LLC (TRC) | 1,174 | $4.05K | 0.00% | −4,558−79.5% | Reduced |
| Nordwand Advisors, LLC | 500 | $1.73K | 0.00% | +500 | New |
| Activest Wealth Management | 9 | $31 | 0.00% | −74−89.2% | Reduced |
| Bank of America Corp | 7 | $24 | 0.00% | −31−81.6% | Reduced |
| Cetera Investment Advisers | 0 | $0 | 0.00% | −35,416−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −28,136−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −24,380−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −23,486−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −21,691−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −14,233−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,457−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |